Stockreport

This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]

Revolution Medicines, Inc.  (RVMD) 
PDF RVMD's FY25 net loss widened to $1.13B on a 67% R&D expense surge, but a $2B cash position and $1.75B in future capital provide strong funding through critical trials. [Read more]